Revolution Medicines disclosed expanded Phase 3 results for daraxonrasib in patients with KRAS-mutant metastatic pancreatic cancer, reporting a median overall survival gain of 13.2 months across the intent-to-treat population versus 6.7 months with chemotherapy. The data were presented at the American Society of Clinical Oncology (ASCO) annual meeting and published alongside in the New England Journal of Medicine, highlighting a survival signal that has not been previously seen in the second-line pancreatic setting. The study tested daraxonrasib in previously treated patients whose tumors were driven by RAS G12 mutations, with KRAS G12/G13 and select other RAS G12/Q61 variants included. In the prespecified mutation subgroup, the drug extended survival to 6.6 months compared with 6.6 months for chemotherapy, while also improving disease control measures including progression-free metrics, with investigators emphasizing rapid symptom and tumor-marker improvements. ASCO plenary presentation details drew attention to the breadth of benefit beyond the biomarker-defined cohort, with the companies and clinicians pointing to a potentially practice-changing efficacy profile and an “expected safety profile” in follow-on discussion from pancreatic cancer specialists.